Drug therapy of inflammatory bowel disease

Drugs of Today

Volumn 34, Issue 5, 1998, Pages 431-446

  Egan, Laurence J ^a   Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOMODULATING AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NICOTINE; OLSALAZINE; TACROLIMUS;

ANTIBIOTIC THERAPY; CLINICAL PROTOCOL; CROHN DISEASE; DRUG MECHANISM; ENTERITIS; ILEITIS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PRACTICE GUIDELINE; PREGNANCY; PROPHYLAXIS; RECURRENT DISEASE; REMISSION; REVIEW; SUPPOSITORY; ULCERATIVE COLITIS;

EID: 0031865335     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1998.34.5.485242     Document Type: Review

References (118)

1. Toy, L.S., Mayer, L. Basic and clinical overview of the mucosal immune system. Semin Gastrointest Dis 1996, 7: 2-11.
2. Azad Khan, A.K., Piris, J., Truelove, S.C. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977, ii: 892-5.
3. Hawkey, C.J., Broughton-Smith, N.K., Whittle, B.J.R. Modulation of human colonic arachadonic acid metabolism by sulphasalazine. Dig Dis Sci 1985, 30: 1161-5.
4. Keshavarzian, A., Morgan, G., Sedghi, S., Gordon, J.H., Doria, M. Role of reactive oxygen metabolites in experimental colitis. Gut 1990, 31: 786-90.
5. Rachmilewitz, D., Karmeli, F., Schwartz, L.W., Simon, P.L, Effect of aminophenols (5ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992, 33: 929-32.
6. Nielsen, O.H., Verspagei, H.W., Elmgreen, J. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment Pharmacol Ther 1988, 2: 203-11.
7. Summers, R.W., Switz, D.M., Sessions, J.T. Jr. et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979, 77: 847-69.
8. Singleton, J.W., Law, D.H., Kelley, M.L. Jr., Mekhjian, H.S., Sturdevant, R.A. National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology 1979, 77: 870-82.
9. Thalen, A., Brattsand, R., Andersson, P.H. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects. Acta Dermato-Venereol 1994, Suppl.: 15-9.
10. Costas, M., Trapp, T., Pereda, M.P. et al. Molecular and functional evidence for in vitro cytokine enhancement of human and murine target cell sensitivity to glucocorticoids. TNFα. priming increases glucocorticoid inhibition of TNF-α-induced cytotoxicity/apoptosis. J Clin Invest 1996, 98: 1409-16.
11. Kodner, I.F. Perianal Crohns disease. In: Inflammatory Bowel Diseases. Allan, R.N. et al. (Eds.)- Churchill Livingstone: New York 1997, 863-72.
12. Harper, P.M., Lee, E.G., Kettlewell, M.G., Bennett, H.K., Jewell, O.P. Role of faecal stream in the maintenance of Crohn's colitis. Gut 1985, 26: 279-84.
13. Rath, H.C., Herfarth, H.H., Ikeda, U.S. et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta, microglobulin transgenic rats. J Clin Invest 1996, 98: 945-53.
14. Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992, 43: 329-39.
15. Sandborn, W.J., Van, O., Zins, B.J., Tremaine, W.J., Mays, D.C., Lipsky, J.J. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995, 109: 1808-17.
16. Egan, L.J., Sandborn, W.J. Methotrexate for inflammatory bowel disease: Pharmacology and preliminary results. Mayo Clin Proc 1996, 71: 69-80.
17. Baggott, J.E., Morgan, S.L., Ha, T.S., Alarcon, G.S., Koopman, W.J., Krumdieck, C.L. Antifolates in rheumatoid arthritis: A hypothetical mechanism of action. Clin Exp Rheumatol 1993, 11 (Suppl. 8): S101-5.
18. Sperling, R.I., Benincaso, A.I., Anderson, R.J., Coblyn, J.S., Austen, K.P., Weinblatt, M.E. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 1992, 35: 376-84.
19. Cronstein, B.N., Eberle, M.A., Gruber, H.E., Levin, R.I. Methotrexate inhibits neutrophif function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991, 88: 2441-5.
20. Cronstein, B.N., Naime, D., Ostad, E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993, 92: 2675-82.
21. Reagan, B., McDonald, J. Methotrexate therapy for chronically active Crohn's disease. Time course of the beneficial effect. Gut 1995, 37: A210.
22. Schroder, H., Foged, E.K. Methotrexate in erythrocytes of patients with psoriasis. Eur J Clin Pharmacol 1986, 30: 453-6.
23. Mueller, E.A., Kovarik, J.M., van Bree, J.B., Tetzloff, W., Grevel, J., Kutz, K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994, 11: 301-4.
24. Stephens, S., Emtage, S., Vetterlein, O. et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995, 85: 668-74.
25. Stack, W.A., Mann, S.D., Roy, A.J. et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997, 349: 521-4.
26. Knight, D.M., Trinh, H., Le, J. et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993, 30: 1443-53.
27. Targan, S.R., Hanauer, S.B., van Deventer, S.J.H- et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New Engl J Med 1997, 337: 1029-35.
28. Yacyshyn, B., Woloschuk, B., Yacyshyn, M.B. et al. Efficacy and safety of ISIS 2302 (ICAM1 antisense oligonucleotide) treatment of steroid dependent Crohn's disease. Gastroenterology 1997, 112: A1123.
29. Neurath, M.F., Pettersson, S., Meyer zum Buschenfelde, K.H., Strober, W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 1996, 2: 998-1004.
30. Schreiber, S., Heinig, T., Thiele, H.G., Raedler, A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995, 108: 1434-44.
31. van Deventer, S.J., Elson, C.O., Fedorak, R.N. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group, Gastroenterology 1997, 113: 383-9.
32. Zijlstra, F.J., Srivastava, E.D., Rhodes, M. et al. Effect of nicotine on rectal mucus and mucosal eicosanoids. Gut 1994, 35: 247-51.
33. Hanauer, S.B. Nicotine for colitis - The smoke has not yet cleared. New Engl J Med 1994, 330: 856-7.
34. Belluzzi, A., Brignola, C., Campieri, M. et al. Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients. Dig Dis Sci 1994, 39: 2589-94.
35. Lofberg, R., Danielsson, A., Suhr, O. et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996, 110: 1713-8.
36. Truelove, S.C. Treatment of ulcerative colitis with local hemisuccinate sodium. A report on a controlled therapeutic trial. Br Med J 1958, 2: 1072-7.
37. Danielsson, A., Lofberg, R., Persson, T. et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis. Scand J Gastroenterol 1992, 27: 9-12.
38. Feurle, G.E., Theuer, D., Velasco, S. et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: A randomised double blind trial. Gut 1989, 30: 1354-61.
39. Hanauer, S., Schwartz, J., Robinson, M. et al. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993, 88: 1188-97.
40. Hetzel, D.J., Shearman, D.J.C., Bochner, F. Azodisalicylate (olsalazine) in the treatment of active ulcerative colitis: A placebo controlled clinical trial and assessment of drug disposition. J Gastroenterol Hepatol 1986, 1: 257-66.
41. Hanauer, S.B., Barish, C., Pambianco, D. et al. A multicenter, double blind, placebo controlled, dose ranging trial of olsalazine for mild-moderatefy active ulcerative colitis. Gastroenterology 1996, 110: A921.
42. Schroeder, K.W., Tremaine, W.J., llstrup, D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New Engl J Med 1987, 317: 1625-9.
43. Sninsky, C.A., Cort, D.H., Shanahan, F. et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 1991, 115: 350-5.
44. Sutherland, L.R., Robinson, M., Onstad, G. A double blind, placebo-controlled, multicentre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcera tive colitis. Can J Gastroenterol 1990, 4: 463-7.
45. Zinberg, J., Molinas, S., Das, K.M. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 1990, 85: 562-6.
46. Levine, D.S., Pruitt, R., Riff, D. et al. A mulit-center, double-blind dose response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology 1997, 112: A1026.
47. Green, J.R.B., Holdsworth, C.D., Lobo, A.J. et at. Balsalazide is more effective and better tolerated than mesalamine in acute ulcerative colitis. Gastroenterology 1997, 112: A984.
48. Sutherland, L.R., Roth, D.E., Beck, P.L. Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 1997, 3: 65-78.
49. Sutherland, S.R., May, G.R., Schaffer, G.A. Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993, 118: 540.
50. Marshall, J.K., Irvine, E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis. Gut 1997, 40: 775-81.
51. Truelove, S.C., Witts, L.J. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955, 4947: 1041-8.
52. Baron, J.H., Connell, A.M., Kanaghinis, T.G., Lennard-Jones, J.E., Avery-Jones, F. Outpatient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962, 2: 441 -3.
53. Powell-Tuck, J., Brown, R.L., Lennard-Jones, J.E. A comparison of oral prednisolone given as a single or multiple daily doses for active proctocolitis, Scand J Gastroenterol 1978, 13: 833-7.
54. Jewell, D.P., Truelove, S.C. Azathioprine in ulcerative colitis: Final report on a controlled therapeutic trial. Br Med J 1974, 4: 627-30.
55. Rosenberg, J.L., Wall, A.J., Levin, B., Binder, H.J., Kirsner, J.B. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975, 69: 96-9.
56. Kirk, A.P., Lennard-Jones, J.E. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982, 284: 1291-2.
57. Pullan, R.D., Rhodes, J., Ganesh, S. et al. Transdermal nicotine for active ulcerative colitis. New Engl J Med 1994, 330: 811-5.
58. Sandborn, W.J., Tremaine, W.J., Offord, K.P. et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997, 126: 364-71.
59. Lichtiger, S., Present, D.H., Kornbluth, A. et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New Engl J Med 1994, 330: 1841-5.
60. Marshall, J.K., Irvine, E.J. Rectal aminosalicylate therapy for distal ulcerative colitis: A meta-analysis. Aliment Pharmacol Ther 1995, 9: 293-300.
61. Miner, P., Hanauer, S., Robinson, M., Schwarte, J., Arora, S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 1995, 40: 296-304.
62. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. Ann Intern Med 1996, 124: 204-11.
63. Hawthorne, A.B., Logan, R.F., Hawkey, C.J. et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992, 305: 20-2.
64. Madden, M.V., McIntyre, A.S., Nicholls, R.J. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994, 39: 1193-6.
65. Sandborn, W.J. Pouchitis following Heal pouch-anal anastomosis: Definition, pathogenesis, and treatment. Gastroenterology 1994, 107: 1856-60.
66. Sachar, D.B., Andrews, H.A., Farmer, R.G. et al. Proposed classification of patient subgroups in Crohn's disease. Gastroenterol Int 1992, 5: 141-54.
67. Rutgeerts, P., Lofberg, R., MaIchow, H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. New Engl J Med 1994, 331: 842-5.
68. Greenberg, G.R., Reagan, B.G., Martin, F. et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. New Engl J Med 1994, 331: 836-41.
69. Malchow, H., Ewe, K., Brandes, J.W. et al. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment. Gastroenterology 1984, 86: 249-66.
70. Singleton, J.W., Hanauer, S.B., Gitnick, G.L. et al. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993, 104: 1293-301.
71. Mahida, Y.R., Jewell, O.P. Slow-release 5-amino-salicy/ic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990, 45: 88-92.
72. Rasmussen, S.N., Lauritsen, K., Tage-Jensen, U. et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987, 22: 877-83.
73. Ewe, K., Press, A.G., Singe, C.C. et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease, Gastroenterology 1993, 105: 367-72.
74. Candy, S., Wright, J., Gerber, M., Adams, G., Gerig, M., Goodman, R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37: 674-8.
75. Willoughby, J.M., Beckett, J., Kumar, P.J., Dawson, A.M. Controlled trial of azathioprine in Crohn's disease. Lancet 1971, 2: 944-7.
76. Present, D.H., Korelitz, B.I., Wisch, N., Glass, J.L., Sachar, D.B., Pasternack, B.S. Treatment of Crohn's disease with 6-mercaptopurine. A Song-term, randomized, doubleblind study. New Engl J Med 1980, 302: 981-7.
77. Pearson, D.C., May, G.R., Pick, G.H., Sutherland, L.R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995, 122: 132-42.
78. Reagan, B.G., Rochon, J., Fedorak, R.N. et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. New Engl J Med 1995, 332: 292-7.
79. Balis, P.M., Mirro, J. Jr., Reaman, G.H. et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988, 6: 1882-6.
80. Sutherland, L., Singleton, J., Sessions, J. et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991, 32: 1071-5.
81. Bernstein, L.H., Frank, M.S., Brandt, L.J., Boley, S.J. Healing of perineal Crohn's dis- ease with metronidazole. Gastroenterology 1980, 79: 357-65.
82. Brandt, L.J., Bernstein, L.H., Boley, S.J., Frank, M.S. Metronidazole therapy for perineal Crohn's disease: A follow-up study. Gastroenterology 1982, 83: 383-7.
83. Steinhart, A.M., Hemphill, D., Greenberg, G.R. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: A meta-analysis. Am J Gastroenterol 1994, 89: 2116-24.
84. Messori, A., Brignola, C., Trallori, G. et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: A meta-analysis. Am J Gastroenterol 1994, 89: 692-8.
85. Gendre, J.P., Mary, J.Y., Florent, C. et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993, 104: 435-9.
86. Belluzzi, A., Brignola, C., Campieri, M., Pera, A., Boschi, S., Miglioli, M. Effect of an entericcoated fish-oil preparation on relapses in Crohn's disease. New Engl J Med 1996, 334: 1557-60.
87. Feagan, B., Greenberg, G.R., Lofberg, R., Ferguson, A., Persson, T. Buesonide controlled Heal release prolongs remission in Crohn's disease: A pooled analysis. Gastroenterology 1997, 112: A970.
88. Rutgeerts, P., Geboes, K., Vantrappen, G., Beyls, J., Kerremans, R-, Hiele, M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99: 956-63.
89. Olaison, G., Smedh, K., Sjodahl, R. Natural course of Crohn's disease after ileocolic resection: Endoscopically visualised Heal ulcers preceding symptoms. Gut 1992, 33: 331-5.
90. Heimann, T.M., Greenstein, A.J., Lewis, B., Kaufman, D., Heimann, D.M., Aufses, A.H. Jr. Prediction of early symptomatic recurrence after intestinal resection in Crohn's disease. Ann Surg 1993, 218: 294-8.
91. Sachar, D.B., Wolfson, D.M., Greenstein, A.J., Goldberg, J., Styczynski, R., Janowitz, H.D. Risk factors for postoperative recurrence of Crohn's disease. Gastroenterology 1983, 85: 917-21.
92. Brignola, C., Cottone, M., Fera, A. et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology 1995, 108: 345-9.
93. McLeod, R.S., Wolff, B.C., Steinhart, A.H. et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995, 109: 404-13.
94. Lochs, H., Mayer, M., Fleig, W.E., Mortensen, P.B., Bauer, P. Prophylaxis of postoperative relapse in Crohn's disease with mesalazine (Pentasa) in comparison to placebo. Gastroenterology 1997, 112: A1027.
95. Rutgeerts, P., Hiele, M., Geboes, K. et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after Heal resection. Gastroenterology 1995, 108: 1617-21.
96. Sturgeon, J.B., Bhatia, P., Hermens, D., Miner, P.B. Exacerbation of chronic ulcerative colitis with mesalamine. Gastroenterology 1995, 108: 1889-93.
97. Weinshilboum, R.M., Sladek, S.L. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32: 651-62.
98. Sandborn, W.J. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996, 91: 423-33.
99. Present, D.H., Meltzer, S.J., Krumholz, M.P., Wolke, A., Korelitz, B.I. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 1989, 111: 641-9.
100. Connell, W.R., Kamm, M.A., Dickson, M., Balkwill, A.M., Ritchie, J.K., Lennard-Jones, J.E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343: 1249-52.
101. Larvol, L., Soule, U.C., Tourneau, A.L. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. New Engl J Med 1994, 331: 883-4.
102. Sternthal, M., George, J., Kornbluth, A., Lichtiger, S., Present, D. Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease. Gastroenterology 1996, 110: A1019.
103. Sandborn, W.J. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995, 1: 48-63.
104. Schnabel, A., Gross, W.L, Low-dose methotrexate in rheumatic diseases Efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994, 23: 310-27.
105. Kremer, J.M., Alarcon, G.S., Lightfoot, R.W., Jr. et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicily. American College of Rheumatology. Arthritis Rheum 1994, 37: 316-28.
106. Duffy, L.F., Daum, F., Fisher, S.E. et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985, 88: 681-4.
107. Willoughby, C.P., Truelove, S.C. Ulcerative colitis and pregnancy. Gut 1980, 21: 469-74.
108. Hanan, I.M., Kirsner, J.B. Inflammatory bowel disease in the pregnant woman. Clin Perinatol 1985, 3: 669.
109. Baird, D.D., Narendranathan, M., Sandler, R.S. Increased risk of pre-term birth for women with inflammatory bowel disease. Gastroenterology 1990, 99: 987.
110. Fedorkow, D.M., Persaud, D., Nimrod, C.A. Inflammatory bowel disease: A controlled study of late pregnancy outcome. Am J Obstet Gynecol 1989, 160: 998.
111. Woolfson, K., Cohen, Z., McLeod, R.S. Crohn's disease and pregnancy. Dis Colon Rectum 1990, 33: 869-73.
112. Nielsen, O.H., Andreasson, B., Bondesen, S., Jacobsen, O., Jarnum, S. Pregnancy in Crohn's disease. Scand J Gastroenterol 1984, 19: 724-32.
113. Habal, F.M., Hui, G., Greenberg, G.R. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: Safety and clinical course. Gastroenterology 1993, 105: 1057-60.
114. Connell, W.R. Safety of drug therapy for inflammatory bowel disease in pregnant and nursing women. Inflamm Bowel Dis 1996, 2: 33-47.
115. Alstead, E.M., Ritchie, J.K., Lennard-Jones, U.E., Farthing, M.J., Clark, M.L. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990, 99: 443-6.
116. Davidson, J.M., Lindheimer, M.D. Pregnancy in women with renal allografts. Semin Nephrol 1984, 4: 240.
117. Mogadam, M., Dobbins, W.O. III, Korelitz, B.I., Ahmed, S.W. Pregnancy in inflammatory bowel disease: Effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981, 80: 72-6.
118. Metcalf, A., Dozois, R.R., Beart, R.W. Jr., Wolff, B.G. Pregnancy following Heal pouchanal anastomosis. Dis Colon Rectum 1985, 28: 859-61.